Roy Chemaly, MD
Enriched profileDepartment Chair and Professor, Infectious Diseases, Infection Control and Employee Health (also holds the endowed Gerald P. Bodey, Sr. Distinguished Professorship) · The University of Texas MD Anderson Cancer Center
Roy Chemaly is Department Chair and Professor, Infectious Diseases, Infection Control and Employee Health (also holds the endowed Gerald P. Bodey, Sr. Distinguished Professorship) at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 911 publications with 21,808 citations (h-index 68); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Infectious Disease profiles in the findmyKOL directory.
Data verified 17 Aug 2026
Overview
Updated 1 Sept 2026
Roy Chemaly, M.D., is Department Chair and Professor, Infectious Diseases, Infection Control and Employee Health (also holds the endowed Gerald P. Bodey, Sr. Distinguished Professorship) at The University of Texas MD Anderson Cancer Center. The public record shows 911 publications with 21,808 citations (h-index 68), centered on Cytomegalovirus and herpesvirus research, Respiratory viral infections research, Hematopoietic Stem Cell Transplantation. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 20 companies, 1 NIH-funded awards (2020–2023).
- Most recent indexed publication: 2026 · Clinical infectious diseases
- Top research focus: Cytomegalovirus and herpesvirus research
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 20 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 21 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 212.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
Sponsor: M.D. Anderson Cancer Center
- A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients
Sponsor: Pulmotect, Inc.
- Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation
Sponsor: Oxford Immunotec
Industry payments
Updated 1 Sept 2026
20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202527 payments$93,155openpaymentsdata.cms.gov ↗
- Biotest AGProgram year20252 payments$15,295openpaymentsdata.cms.gov ↗
- Shionogi IncProgram year20256 payments$10,046openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Tetracycline-class Drug100%Minocycline Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 1 Sept 2026
1 NIH research award on record, funded 2020–2023 per NIH RePORTER. The latest:
- The interplay of the immune system, and microbiome in determining outcome of respiratory viral infections in hematopoietic cell transplant recipients and in patients with leukemia
University of Tx Md Anderson Can Ctr
FY2023$126,629R01CA246368 - The interplay of the immune system, and microbiome in determining outcome of respiratory viral infections in hematopoietic cell transplant recipients and in patients with leukemia
University of Tx Md Anderson Can Ctr
FY2022$125,604R01CA246368 - The interplay of the immune system, and microbiome in determining outcome of respiratory viral infections in hematopoietic cell transplant recipients and in patients with leukemia
University of Tx Md Anderson Can Ctr
FY2021$127,149R01CA246368
Congress activity
Updated 1 Sept 2026
6 congress contributions (2017–2021) across ASCO, ASH per OpenAlex. The most recent:
- Real-world patient-reported and clinical outcomes of BNT162b2 mRNA COVID-19 vaccine in patients with cancer.
ASCO Annual Meeting
ASCO2021Co-author - Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections
ASH Annual Meeting
ASH2021Co-author - Freesia Study Design: JNJ-53718678 in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
ASH Annual Meeting
ASH2019Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 1 Sept 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T Cells.
Clinical infectious diseases
Article2026 - Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli.
Antimicrobial agents and chemotherapy
Article2026 - A decade of change: evolving epidemiology of invasive pulmonary mold infections in hematologic malignancy patients from a longitudinal infection control surveillance program.
Infection control and hospital epidemiology
Article2026
Most-cited works
by citation count (OpenAlex)- 01Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patientsArticle4,775 citations2017
- 02Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationArticle1,226 citations2017
- 03
- 04
- 05Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell TransplantationArticle374 citations2014
Network
Updated 1 Sept 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/roy-chemaly-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Roy-Chemaly
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
mdanderson.org/cancerwise/tripledemic-insights--when-covid-19--flu-and-rsv-collide.h00-159544479.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 1 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- Chair
The European Society for Clinical Microbiology and Infectious Diseases Study Group for Respiratory Viruses (ESGREV)
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Chair
Updated Guidelines for CMV Infections in Hematopoietic Cell Transplant and Cellular Therapy Recipients, The American Society for Transplant and Cellular Therapy (ASTCT)
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Achievement Award in the Field of Infectious Diseases
The Lebanese Order of Physicians, Beirut, Lebanon
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- Adjunct Professor
Baylor College of Medicine, Houston, TX
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Adjunct Professor
The University of Texas School of Public Health, Houston, TX
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center